— Know what they know.
/
Not Investment Advice

ABBV

NYSE · USD
AbbVie Inc.
Healthcare · Drug Manufacturers - General
CEO Robert A. Michael Employees 57,000 R&D / revenue 14.9%
Last price
$285.42+0.71%last session
Market cap
$504.4B
P/E (TTM)
80.4x
From 52w high
−2.1%
From 52w low
+49.6%
1-year return
+25.8%
RSI 14 · vs SMA200
71.1 · +22.2%
IS score
66.6/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

ABBV   SPY   XLV (sector ETF) · weekly closes
90100110120Jan 26Apr 26Jul 26Oct 26ABBV 126XLV 124SPY 116

Score DNA

Each bar is a 0-100 score within the scored universe
62
Profitability
76
Growth
32
Value
91
Momentum
50
Risk (safety)
72
Quality
26
Balance sheet
59
Earnings quality

Flags

Strengths
✓ Congress buying
Warnings
None of the computed warning flags fires for ABBV (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Narrow, Efficient ScalePiotroski 7 / 9Altman Z 2.4Beta 0.283 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
0
1 open-market sales, $8.2M
Form 144 notices (12m): 5, $21.7M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
1
Last disclosed purchase 2026-05-01
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
+124
287 new holders, 111 closed
4,196 filers hold 75.8% · 1,919 added, 1,526 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+219
1,820 funds adding shares
1,601 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
39.5%
20-day avg 48.0%, 50-day avg 50.3%
Latest 8.5 pp under its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$61.2B
Revenue growth YoY+8.6%
Gross margin83.7%
Operating income$21.2B
Operating margin34.7%
Net income$4.2B
Net margin6.9%
EPS (diluted)$2.36
Cash flow
Operating cash flow$19.0B
Capital expenditure$1.2B
Free cash flow$17.8B
FCF conversion (FCF / OCF)93.6%
Stock-based compensation$955.0M
FCF less SBC$16.9B
Buybacks$980.0M
Dividends$11.7B
Balance sheet & returns
Cash & short-term investments$5.3B
Total debt$68.4B
Net debt$63.1B
Shareholders' equity−$3.2B
Goodwill & intangibles$88.3B
Debt / equity-11.93
ROE (TTM)-136.5%
ROIC (TTM)13.5%
Operating margin by fiscal year
31.9%FY202131.2%FY202223.5%FY202316.2%FY202428.3%FY2025
Revenue $56.2B (FY2021) to $61.2B (FY2025), a 2.1% CAGR.

Valuation

P/E (TTM)80.4x
EV / EBITDA26.8x
Price / sales7.83x
Price / FCF27.7x
FCF yield3.61%
Buyback yield0.19%
SBC / revenue1.5%
Price / bookn/m
Forward P/E FY202620.5x
Forward P/E FY202717.4x
Forward P/E FY202816.0x
Forward multiples divide today's price by Street EPS estimates. Street mean target $299.50 across 12 analysts last quarter is theirs, not ours.

ABBV vs industry median

40 companies in Drug Manufacturers - General
Gross margin 71.5% 72.4% Operating margin 29.3% 20.1% Net margin 9.8% 12.7% ROIC 13.5% 16.2%
ABBV (TTM)Industry median Asset turnover 0.48 vs industry 0.54 · financial leverage -22.77

Earnings delivery

Next report 2026-10-30 · consensus EPS $3.74
92%
beat rate, 11 of 12 quarters
+2.5%
median EPS surprise
6
longest beat streak
+3+1+2+3+3-28+3+3+5+2+2+1
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-10-27 to 2026-07-31. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
ABBV AbbVie Inc. $504.4B80.4x-136.5%9.8%+8.6% +25.8%
JNJ Johnson & Johnson $615.9B38.7x25.7%21.9%+8.1% +33.9%
MRK Merck & Co., Inc. $360.1B115.8x7.0%-8.0%+4.5% +75.4%
NVS Novartis AG $286.3B22.9x30.6%22.7%+0.8% +15.1%
AZN AstraZeneca PLC $256.5B24.7x22.0%16.3%+8.6% −1.5%
AMGN Amgen Inc. $233.8B26.7x91.5%23.6%+9.2% —
LLY Eli Lilly and Company $1.18T42.1x102.4%30.9%+49.6% —
GILD Gilead Sciences, Inc. $193.7Bn/m-20.6%—+5.5% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-10-15Officer/Director Change
2026-10-05Earnings Release; Exhibits
2026-09-03Regulation FD; Exhibits
2026-08-18Other Events; Exhibits
2026-08-05Other Events; Exhibits
2026-07-31Earnings Release; Exhibits

Context

Shares outstanding1,767,117,285
Free float99.8%
Institutional ownership75.8%
Beta0.28
Dividend yield2.42%
Last dividend$1.73 on 2026-10-15
50 / 200-day average$261.62 / $233.67
Mega-cap Healthcare median P/E20.1x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Narrow).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where ABBV sits among 12 scored companies in Drug Manufacturers - General (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureABBVIndustry medianIndustry percentileSector median
P/E (TTM) 79.9x 29.3x
90th		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) —
Price / sales 7.8x 5.3x
91st		 3.7x
Price / book —
Price / tangible book —
Price / free cash flow 26.4x 20.3x
82nd		 21.2x
Price / operating cash flow 25.9x 16.8x
82nd		 17.1x
Enterprise value $568.6B $280.5B
82nd		 $2.5B
EV / sales 8.8x 6.0x
91st		 3.8x
EV / EBITDA 26.8x 18.0x
73rd		 16.2x
EV / EBIT 42.7x 24.8x
90th		 23.0x
EV / free cash flow 29.8x 23.7x
82nd		 24.6x
Earnings yield 1.3% 3.0%
18th		 -0.3%
FCF yield 3.8% 5.0%
18th		 1.7%
Operating cash flow yield 3.9% 6.0%
18th		 2.9%
Graham number (per share) —

Profitability (TTM)

MeasureABBVIndustry medianIndustry percentileSector median
Gross margin 71.5% 72.1%
45th		 65.1%
EBITDA margin 32.9% 32.8%
55th		 6.6%
Operating margin 29.3% 25.2%
73rd		 3.5%
EBIT margin 20.7% 22.0%
45th		 2.4%
Net margin 9.8% 13.4%
45th		 0.3%
NOPAT margin 21.3% 20.5%
55th		 2.7%
FCF margin 29.7% 24.7%
82nd		 4.3%
Operating cash flow margin 30.3% 29.5%
64th		 7.1%
R&D / revenue 15.1% 20.0%
9th		 12.4%
SG&A / revenue 22.8% 22.0%
55th		 37.9%
Stock comp / revenue 1.5% 1.1%
100th		 4.5%
Effective tax rate 27.4% 19.2%
82nd		 21.0%

Returns on capital

MeasureABBVIndustry medianIndustry percentileSector median
ROE (on average equity) —
ROA 4.6% 6.9%
45th		 -0.3%
ROIC 23.5% 15.9%
91st		 5.5%
ROCE 14.2% 15.6%
45th		 2.3%
Return on tangible assets 9.8% 11.2%
45th		 1.7%
Cash ROIC (OCF / invested capital) 33.4% 22.4%
82nd		 9.7%
Gross profitability (GP / assets) 34.1% 34.0%
55th		 29.9%
ROIC, 3-yr average 10.8% 10.3%
55th		 2.6%
ROIC, 5-yr average —
ROE, 5-yr average —
Incremental ROIC -202.7% 4.4%
18th		 17.2%

Growth

MeasureABBVIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 10.4% 5.0%
91st		 10.5%
Revenue growth (QoQ) 13.3% 8.6%
82nd		 7.2%
Revenue CAGR, 3 yr 4.7% 4.4%
64th		 10.7%
Revenue CAGR, 5 yr 3.7% 3.3%
55th		 12.1%
Gross profit CAGR, 3 yr 6.0% 5.9%
55th		 10.6%
Operating income CAGR, 3 yr 2.8% 10.0%
30th		 11.7%
Net income growth (TTM YoY) 67.5% -6.6%
80th		 17.5%
Net income CAGR, 3 yr -10.1% 3.1%
30th		 11.3%
EPS growth (TTM YoY) 67.6% -4.3%
70th		 19.2%
EPS CAGR, 3 yr -10.1% 2.7%
30th		 14.0%
EPS CAGR, 5 yr -1.0% 2.2%
44th		 8.1%
FCF growth (TTM YoY) 4.7% 4.7%
50th		 18.6%
FCF CAGR, 3 yr -8.3% 11.3%
0th		 15.4%
Operating cash flow CAGR, 3 yr -8.6% 6.8%
0th		 11.9%
Book value CAGR, 3 yr —
Dividend CAGR, 3 yr 1.8% 1.8%
50th		 2.2%
Sustainable growth rate —

Margin history & stability

MeasureABBVIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 69.5% 70.1%
45th		 62.6%
Operating margin, 3-yr average 24.0% 23.5%
55th		 1.0%
Net margin, 3-yr average 8.7% 13.4%
27th		 -2.6%
FCF margin, 3-yr average 31.1% 22.0%
91st		 3.2%
Revenue stability (0-1) 0.72 0.75
45th		 0.80
Earnings stability (0-1) 0.30 0.23
55th		 0.37
Margin stability (0-1) 0.93 0.94
45th		 0.93

Liquidity (latest quarter)

MeasureABBVIndustry medianIndustry percentileSector median
Cash & short-term investments $6.6B $7.4B
36th		 $330.9M
Net cash (− = net debt) −$64.3B −$36.7B
0th		 $8.4M
Working capital −$8.0B $4.1B
0th		 $381.1M
Current ratio 0.81 1.29
0th		 3.02
Quick ratio 0.69 1.05
18th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.16 0.31
9th		 1.43
Defensive interval (days) 274 days 287 days
45th		 415 days

Leverage & solvency (latest quarter)

MeasureABBVIndustry medianIndustry percentileSector median
Total debt $70.8B $49.0B
100th		 $289.1M
Debt / equity —
Net debt / equity —
Debt / assets 52.4% 40.8%
73rd		 24.4%
Debt / capital —
Debt / EBITDA 3.34 3.30
55th		 2.62
Net debt / EBITDA 3.03 2.75
55th		 1.42
Interest coverage (EBIT / interest) 4.6x 5.3x
36th		 2.1x
Cash interest coverage 6.7x 9.8x
27th		 3.6x
Debt payback (years of OCF) 3.6 yrs 2.8 yrs
73rd		 2.7 yrs
Liabilities / assets 104.3% 71.1%
100th		 49.8%
IS credit model rating BB- — —
Implied credit spread (bps) 550 250
91st		 225

Efficiency

MeasureABBVIndustry medianIndustry percentileSector median
Asset turnover 0.47 0.49
36th		 0.56
Fixed asset turnover 11.11 4.31
100th		 4.87
Inventory turnover 3.6 2.1
91st		 2.7
Receivables turnover 4.9 4.9
45th		 6.4
Days sales outstanding 75 days 74 days
55th		 57 days
Days inventory outstanding 100 days 172 days
9th		 136 days
Days payables outstanding 646 days 116 days
91st		 59 days
Cash conversion cycle (days) −471 days 126 days
0th		 70 days
Capex / revenue 0.6% 4.6%
0th		 2.6%
Capex / depreciation 0.05 0.49
0th		 0.55
Operating expense ratio 36.9% 40.9%
18th		 56.5%

Cash flow & earnings quality

MeasureABBVIndustry medianIndustry percentileSector median
Operating cash flow / net income 3.09 1.44
60th		 1.61
FCF / net income 3.02 1.24
80th		 1.36
FCF / operating cash flow 97.9% 81.5%
100th		 81.2%
Capex / operating cash flow 2.1% 18.5%
0th		 18.8%
Accruals ratio -9.7% -4.3%
18th		 -5.4%
Sloan accruals ratio -3.9% -2.6%
36th		 -1.3%
Earnings quality score (0-1) 0.75 1.00
0th		 0.75

Dividends & buybacks

MeasureABBVIndustry medianIndustry percentileSector median
Dividend yield 2.4% 2.2%
73rd		 0.0%
Dividend per share (TTM) $6.92 $3.33
91st		 $0.00
Payout ratio (dividends / net income) 189.7% 60.0%
80th		 0.0%
Dividends / FCF 62.7% 50.8%
82nd		 0.0%
Dividend growth (YoY) 5.7% 5.0%
70th		 4.5%
Buyback yield 0.3% 0.1%
64th		 0.0%
Shareholder yield (dividends + buybacks) 2.7% 2.5%
55th		 0.0%
Share count change (YoY) -0.1% -0.1%
55th		 2.0%
Buybacks, last 5 years $6.6B $3.6B
64th		 $0

Scores & forensic checks

MeasureABBVIndustry medianIndustry percentileSector median
IS score 67 64
64th		 46
IS profitability 62 67
45th		 22
IS growth 76 40
91st		 60
IS value 32 42
9th		 39
IS momentum 91 67
91st		 67
IS risk (safety) 50 72
9th		 80
IS quality 72 72
45th		 49
IS balance sheet 26 49
9th		 55
IS earnings quality 59 68
18th		 56
IS cash flow 77 66
82nd		 41
Piotroski F-score (0-9) 7 7
45th		 5
Altman Z-score 2.4 3.0
27th		 3.2
Beneish M-score −2.82 −2.72
27th		 −2.62
Ohlson O-score −7.50 −8.11
73rd		 −7.16
IS credit score 40 60
9th		 62

Per share

MeasureABBVIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $3.57 $5.07
36th		 −$0.03
Book value per share −$3.35 $19.22
0th		 $7.10
Tangible book per share −$51.12 −$8.38
0th		 $1.91
Revenue per share $36.36 $32.71
55th		 $9.38
FCF per share $10.78 $7.97
73rd		 $0.46
Operating cash flow per share $11.01 $9.66
73rd		 $0.93
Cash per share $3.71 $4.10
36th		 $3.51

Size (TTM)

MeasureABBVIndustry medianIndustry percentileSector median
Market cap $504.4B $245.2B
82nd		 $2.4B
Revenue $64.4B $58.5B
73rd		 $770.2M
EBITDA $21.2B $16.9B
73rd		 $56.1M
Net income $6.3B $7.5B
45th		 −$3.3M
Free cash flow $19.1B $12.3B
91st		 $41.2M
Total assets $135.1B $118.9B
73rd		 $1.3B
Shareholders' equity −$5.9B $28.1B
0th		 $568.4M
Employees 57,000 53,500
55th		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-09-30Quaggin Susan E
Director
 Award / grant 59$261.59$15,434918
2026-09-30Rapp Edward J
Director
 Award / grant 129$261.59$33,74529,568
2026-08-14Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
 Option exercise 32,710$79.02$2.6M107,140
2026-08-14Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
 Open-market sale 32,710$250.00$8.2M74,430
2026-08-14Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
 Option exercise 32,710$79.02$2.6M0
2026-06-30Rapp Edward J
Director
 Award / grant 134$251.64$33,72029,236
2026-06-30Quaggin Susan E
Director
 Award / grant 62$251.64$15,602853
2026-05-08Falk Thomas J
Director
 Award / grant 1,118——2,321
2026-05-08Waddell Frederick H
Director
 Award / grant 1,118——30,076
2026-05-08Roberts Rebecca B
Director
 Award / grant 1,118——14,846
2026-05-08Rapp Edward J
Director
 Award / grant 1,118——45,964
2026-05-08Quaggin Susan E
Director
 Award / grant 1,118——3,643

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarMayJunAugSep

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired1512,682$98,500
Open-market saleDisposed132,710$8.2M
Option exerciseAcquired132,710$2.6M
Option exerciseDisposed132,710$2.6M
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

12 months: 5 notices · 91,989 shares · $21.7M
FiledFilerShares proposedEst. proceeds
2026-08-14Nicholas Donoghoe32,710$8.2M
2026-05-26Robert J Alpern13,000$2.8M
2026-03-06David R. Purdue5,230$1.2M
2026-03-02Perry C Siatis18,668$4.4M
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 22 trades (3 purchases) · Senate 0 (0 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-09-14Pete SessionsHouseSale$15,001 - $50,0002026-09-21
2026-09-04Ro KhannaHouseSale$15,001 - $50,0002026-10-09
2026-05-05Josh GottheimerHouseSale$1,001 - $15,0002026-06-04
2026-05-05Josh GottheimerHouseSale (Full)$1,001 - $15,0002026-06-04
2025-08-22John BoozmanSenateSale$1,001 - $15,0002025-09-13
2025-08-22John BoozmanSenateSale (Partial)$1,001 - $15,0002025-09-12
2025-08-22John BoozmanSenateSale$1,001 - $15,0002025-09-12
2025-08-22John BoozmanSenateSale (Partial)$1,001 - $15,0002025-09-11
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
BlackRock, Inc.149,488,412$37.6B8.46%
VANGUARD CAPITAL MANAGEMENT LLC115,396,098$29.0B6.53%
STATE STREET CORP82,596,748$20.8B4.67%
VANGUARD PORTFOLIO MANAGEMENT LLC48,477,996$12.2B2.74%
GEODE CAPITAL MANAGEMENT, LLC46,998,433$11.8B2.66%
JPMORGAN CHASE & CO45,680,760$11.6B2.59%
Capital Research Global Investors30,101,551$7.6B1.70%
NORGES BANK25,554,538$6.4B1.45%
BANK OF AMERICA CORP /DE/21,237,764$5.3B1.20%
FMR LLC20,773,786$5.2B1.18%
FRANKLIN RESOURCES INC19,924,183$5.0B1.13%
Capital World Investors19,178,966$4.8B1.09%
GOLDMAN SACHS GROUP INC16,291,630$4.1B0.92%
Capital International Investors15,638,631$3.9B0.88%
NORTHERN TRUST CORP14,897,534$3.7B0.84%

Institutional ownership by quarter

2023-092026-0675.8%
% of shares held by 13F filers
2023-092026-064,196
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-304,19675.8%2871,9191,526111
2026-03-314,07273.2%2061,7221,685180
2025-12-314,11874.2%4731,5941,611116
2025-09-303,85871.5%2951,6501,444102
2025-06-303,73472.8%1871,6861,448163
2025-03-313,76772.5%2671,4841,591127
2024-12-313,69471.8%4481,4861,378128
2024-09-303,44271.4%2441,4121,36574
2024-06-303,31171.2%1581,4541,290124
2024-03-313,32370.6%2221,3281,453116
2023-12-313,26769.8%3681,1551,39794
2023-09-303,05069.0%1771,2551,253102

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-03-26SCHEDULE 13G/AThe Vanguard Group0.0%0
2025-07-07SCHEDULE 13G/AThe Vanguard Group10.0%177,266,703
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.63%$14.7B
VTSAX0.63%$14.7B
VSMPX0.63%$14.7B
VTI0.63%$14.7B
VFFSX0.70%$12.1B
VFIAX0.70%$12.1B

Share structure

Shares outstanding1,767,117,285
Float1,763,989,487
Free float99.8%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$56.2B$58.1B$54.3B$56.3B$61.2B
Cost of revenue$17.4B$17.4B$20.4B$16.9B$10.0B
Gross profit$38.8B$40.6B$33.9B$39.4B$51.2B
R&D$8.0B$6.5B$7.7B$12.8B$9.1B
SG&A$12.3B$15.3B$12.9B$13.2B$14.0B
Operating income$17.9B$18.1B$12.8B$9.1B$21.2B
EBITDA$23.9B$24.2B$17.2B$14.9B$28.3B
Pretax income$13.0B$13.5B$6.2B$3.7B$6.6B
Income tax$1.4B$1.6B$1.4B−$570.0M$2.4B
Net income$11.5B$11.8B$4.9B$4.3B$4.2B
EPS, diluted$6.45$6.63$2.72$2.39$2.36
Diluted shares1.8B1.8B1.8B1.8B1.8B

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$9.8B$9.2B$12.8B$5.6B$5.3B
Receivables$10.0B$11.3B$11.2B$10.9B$12.6B
Inventory$3.1B$3.6B$4.1B$4.2B$5.0B
Total current assets$27.9B$28.5B$33.0B$25.6B$29.1B
PP&E, net$5.1B$4.9B$5.0B$5.1B$6.4B
Goodwill & intangibles$108.3B$99.6B$87.9B$95.0B$88.3B
Total assets$146.5B$138.8B$134.7B$135.2B$134.0B
Accounts payable$2.9B$2.9B$3.7B$2.9B$3.6B
Total current liabilities$35.2B$29.5B$37.8B$38.7B$43.3B
Long-term debt$64.2B$59.1B$52.2B$60.3B$59.6B
Total liabilities$131.1B$121.5B$124.3B$131.8B$137.2B
Shareholders' equity$15.4B$17.3B$10.4B$3.4B−$3.2B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$11.5B$11.8B$4.8B$4.3B$4.2B
Depreciation & amortization$8.5B$8.5B$8.7B$8.4B$8.1B
Stock-based compensation$692.0M$671.0M$747.0M$911.0M$955.0M
Change in working capital−$1.3B−$258.0M$2.8B−$2.8B−$2.4B
Operating cash flow$22.8B$24.9B$22.8B$18.8B$19.0B
Capital expenditure−$787.0M−$695.0M−$777.0M−$974.0M−$1.2B
Free cash flow$22.0B$24.2B$22.1B$17.8B$17.8B
Investing cash flow−$2.3B−$623.0M−$2.0B−$20.8B−$6.6B
Net debt issued / repaid−$8.4B−$12.4B−$4.1B$7.3B−$327.0M
Buybacks−$934.0M−$1.5B−$2.0B−$1.7B−$980.0M
Dividends paid−$9.3B−$10.0B−$10.5B−$11.0B−$11.7B

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin69.0%70.0%62.4%70.0%73.4%
Operating margin31.9%31.2%23.5%16.2%28.3%
Net margin20.5%20.4%9.0%7.6%6.9%
FCF margin39.1%41.8%40.6%31.7%30.6%
ROE81.0%72.5%35.2%62.5%15,389.1%
ROIC19.2%22.0%17.2%16.1%18.3%
ROA7.8%8.3%3.6%3.2%3.1%
Debt / equity5.033.725.8020.40-21.12
Interest coverage6.4x7.0x3.8x2.3x3.3x
Current ratio0.790.960.870.660.67
Revenue growth+22.7%+3.3%−6.4%+3.7%+8.6%
EPS growth+150.5%+2.5%−58.8%−12.1%−1.1%
P/E at year end18.0x21.8x52.6x71.2x95.8x
EV / EBITDA at year end11.5x12.9x17.7x24.6x26.6x
FCF yield at year end10.59%9.42%8.62%5.86%4.61%
Dividend payout80.2%84.9%216.7%257.7%275.4%

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
H U M I R A$20.7B$21.2B$14.4B$9.0B$4.5B
SKYRIZI$2.9B$5.2B$7.8B$11.7B$17.6B
RINVOQ$1.7B$2.5B$4.0B$6.0B$8.3B
Imbruvica$5.4B$4.6B$3.6B$3.3B$2.9B
Other Products$2.7B$4.1B$3.0B$3.0B$2.6B
Botox Therapeutic$2.5B$2.7B$3.0B$3.3B$3.8B
Vraylar—$2.0B$2.8B$3.3B$3.6B
VENCLEXTA$1.8B$2.0B$2.3B$2.6B$2.8B
Botox Cosmetic$2.2B$2.6B$2.7B$2.7B$2.6B
MAVYRET$1.7B$1.5B$1.4B$1.3B$1.3B
Juvederm Collection$1.5B$1.4B$1.4B$1.2B$993.0M
Other Aesthetics$1.5B$1.3B$1.2B$1.3B$1.3B
Restasis$1.3B$666.0M$436.0M$224.0M—
Ubrelvy——$815.0M$1.0B$1.3B
Other Eye Care$1.2B$1.2B$803.0M$847.0M$1.0B
Linzess/Constella$1.0B$1.0B$1.1B$954.0M$907.0M
Qulipta——$408.0M$658.0M$1.0B
Other Neuroscience$685.0M$475.0M$276.0M$338.0M$207.0M
Lumigan/Ganfort$579.0M$514.0M$432.0M$429.0M$410.0M
Alphagan/Combigan$529.0M$346.0M$272.0M$248.0M$197.0M
Duodopa$511.0M$458.0M$468.0M$447.0M$381.0M
Ozurdex——$472.0M$494.0M$493.0M

Revenue by region · FY2025

UNITED STATES$46.6B · 95%
Non-US$2.4B · 5%

Street estimates by fiscal year

Next report 2026-10-30 · consensus EPS $3.74 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$67.6B$67.5B – $68.0B$13.95$13.79 – $14.231520.5x
2027$73.5B$71.9B – $74.9B$16.38$15.52 – $17.371417.4x
2028$79.0B$75.2B – $81.6B$17.88$15.47 – $20.89816.0x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-07-31$3.61$3.65+1.1%$16.8B$17.0B+1.1%
2026-04-29$2.59$2.65+2.3%$14.7B$15.0B+1.9%
2026-02-04$2.65$2.71+2.3%$16.4B$16.6B+1.2%
2025-10-31$1.77$1.86+5.1%$15.6B$15.8B+1.2%
2025-07-31$2.88$2.97+3.1%$15.0B$15.4B+2.6%
2025-04-25$2.38$2.46+3.4%$12.9B$13.3B+3.2%
2025-01-31$2.98$2.16−27.5%$14.8B$15.1B+1.8%
2024-10-30$2.92$3.00+2.7%$14.3B$14.5B+1.2%
2024-07-25$2.57$2.65+3.1%$14.0B$14.5B+3.1%
2024-04-26$2.26$2.31+2.2%$11.9B$12.3B+3.2%
2024-02-02$2.76$2.79+1.1%$13.0B$14.3B+10.2%
2023-10-27$2.86$2.95+3.1%$13.7B$13.9B+1.9%
2023-07-27$2.79$2.91+4.3%$13.5B$13.9B+2.6%
2023-04-27$2.44$2.46+0.8%$12.2B$12.2B+0.5%
2023-02-09$3.54$3.60+1.7%$15.3B$15.1B−1.4%
2022-10-28$3.56$3.66+2.8%$15.0B$14.8B−1.0%
2022-07-29$3.31$3.37+1.8%$14.7B$14.6B−0.6%
2022-04-29$3.14$3.24+3.2%$13.6B$13.5B−0.5%
2022-02-02$3.29$3.31+0.6%$15.0B$14.9B−0.4%
2021-10-29$3.23$3.33+3.1%$14.4B$14.3B−0.1%
2021-07-30$3.11$3.110.0%$14.0B$14.0B0.0%
2021-04-30$2.77$2.95+6.5%$12.8B$13.0B+1.6%
2021-02-03$2.85$2.92+2.5%$13.7B$13.9B+1.0%
2020-10-30$2.75$2.83+2.9%$12.6B$12.9B+2.2%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
1.006-152.706-221.706-291.707-061.607-131.107-202.107-271.708-031.108-101.508-171.008-241.208-31
Week ofNotionalSharesTrades
2026-08-31$1.2B4,478,69493,028
2026-08-24$974.3M3,737,31587,643
2026-08-17$1.5B5,910,024112,495
2026-08-10$1.1B4,582,60795,171
2026-08-03$1.7B6,856,512129,010
2026-07-27$2.1B7,916,968154,813

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1539.5%
DateShort shareShort volumeTotal volume
2026-10-1539.5%1,115,5442,823,717
2026-10-1458.1%1,207,0192,077,676
2026-10-1341.4%875,0232,111,077
2026-10-1252.4%775,1761,479,772
2026-10-0946.9%658,2101,403,245
2026-10-0851.8%760,3311,469,039
2026-10-0748.8%982,0602,013,441
2026-10-0657.0%787,1631,380,319
2026-10-0551.1%1,157,0242,263,783
2026-10-0263.9%1,085,7051,699,322
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
-1.1Jan+3.3Feb-0.8Mar+2.6Apr-0.4May+1.4Jun+1.4Jul+0.3Aug+2.3Sep+1.0Oct+4.9Nov+2.9Dec
MonthAvg returnUp yearsYears
Jan−1.1%36%14
Feb+3.3%71%14
Mar−0.8%57%14
Apr+2.6%62%13
May−0.4%31%13
Jun+1.4%62%13
Jul+1.4%62%13
Aug+0.3%46%13
Sep+2.3%54%13
Oct+1.0%62%13
Nov+4.9%69%13
Dec+2.9%69%13
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1471.1
MFI61.4
ADX28.3
Stochastic %K / %D84.4 / 82.8
Williams %R-17.0
CCI167
TSI / signal31.1 / 20.6
Chaikin money flow0.10
ATR$6.46
Bollinger width11.6%
Volume vs 20-day avg1.16x
SupertrendUp

Moving averages and bands

level (price vs level)
SMA 20$269.02 (+6.1%)
SMA 50$262.09 (+8.9%)
SMA 200$233.59 (+22.2%)
EMA 21$270.65 (+5.5%)
EMA 50$262.79 (+8.6%)
EMA 200$239.31 (+19.3%)
Bollinger upper$284.64 (+0.3%)
Bollinger lower$253.40 (+12.6%)
Parabolic SAR$266.53 (+7.1%)
Open the live chart, 110+ indicators

About AbbVie Inc.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

https://www.abbvie.com

Key executives

NameTitlePayBorn
Robert A. MichaelChief Executive Officer & Chairman of the Board$7.4M1970
Jeffrey Ryan StewartExecutive Vice President & Chief Commercial Officer$5.0M1969
Azita SalekiExecutive Vice President & Chief Operating Officer$4.1M1963
Scott T. ReentsExecutive Vice President & Chief Financial Officer$3.9M1967
Demetris D. CrumExecutive Vice President & Chief Human Resources Officer$3.8M1981
Roopal ThakkarExecutive Vice President of Research and Development & Chief Scientific Officer$3.6M1972
Linda RaySenior VP & Chief Information Officer——
Perry C. SiatisExecutive Vice President, General Counsel & Secretary—1975

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
Robert A. Michael Chairman of the Board and Chief Executive Officer2025$1.7M$13.3M$5.2M$32.5M
Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer2025$1.3M$5.4M$3.0M$15.4M
Scott T. Reents Executive Vice President, Chief Financial Officer2025$1.1M$4.4M$2.4M$12.4M
Azita Saleki-Gerhardt Executive Vice President, Chief Operations Officer2025$1.1M$4.0M$2.2M$10.8M
Roopal B. Thakkar Executive Vice President, Research & Development and Chief Scientific Officer2025$1.1M$4.0M$2.4M$9.9M

Employees

30k201830k201947k202050k202150k202250k202355k202457k2025

Dividends

Ex-dateAmountPaid
2026-10-15$1.732026-11-16
2026-07-15$1.732026-08-14
2026-04-15$1.732026-05-15
2026-01-16$1.732026-02-17
2025-10-15$1.642025-11-14
2025-07-15$1.642025-08-15
2025-04-15$1.642025-05-15
2025-01-15$1.642025-02-14

Moat model

Narrow · Efficient Scale · 2026-06-30
Cost advantage67
Intangibles65
Switching costs52
Network effect50
Efficient scale75
Our component scores (0-100) and overall 61.4; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms